Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 3/20 | 0.46 |
| ▸ | GRM5 | P41594 | 3/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 7/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | SCD | O00767 | 1/20 | 0.35 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.35 |
| ▸ | PRF1 | P14222 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | CTSD | P07339 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4686107 | 0.87 | GRM5 (0.39) | PGRGRM5BACE1CYP11B2 | |
| SCHEMBL13707061 | 0.87 | GRM5 (0.53) | PGRGRM5BACE1CYP11B2CTSD | |
| SCHEMBL4683347 | 0.85 | RPS6KB1 (0.42) | PGRGRM5CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL6103044 | 0.83 | PGR (0.44) | PGRGRM5BACE1FAAHCYP11B2 | |
| SCHEMBL4427166 | 0.82 | GRM5 (0.46) | PGRGRM5CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL4431361 | 0.82 | PGR (0.52) | PGRGRM5CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL4680546 | 0.79 | GRM5 (0.44) | PGRGRM5BACE1PRF1CYP11B2 | |
| SCHEMBL4679394 | 0.78 | GRM5 (0.36) | GRM5CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL13707001 | 0.74 | GRM5 (0.46) | PGRGRM5BACE1CYP11B2 | |
| SCHEMBL4686098 | 0.74 | GRM5 (0.44) | PGRGRM5CYP3A4CYP2C19BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1943247-A1 | TETRAHYDROQUINOLINONES AND THEIR USE AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Merz Pharma GmbH & Co.KGaA (DE) | 2008-07-16 | — | — | EP | claimed |
| WO-2007023245-A1 | TETRAHYDROQUINOLINONES AND THEIR USE AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2007-03-01 | — | — | WO | claimed |
| US-20060004001-A1 | Tetrahydroquinolones and their use as modulators of metabotropic glutamate receptors | MERZ PHARMA GMBH & CO., KGAA (DE) | 2006-01-05 | — | — | US | claimed |
| EP-1943247-A1 | TETRAHYDROQUINOLINONES AND THEIR USE AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Merz Pharma GmbH & Co.KGaA (DE) | 2008-07-16 | — | — | EP | disclosed |
| WO-2007023245-A1 | TETRAHYDROQUINOLINONES AND THEIR USE AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2007-03-01 | — | — | WO | disclosed |
| WO-2007023245-A1 | TETRAHYDROQUINOLINONES AND THEIR USE AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2007-03-01 | — | — | WO | disclosed |
| US-20060004001-A1 | Tetrahydroquinolones and their use as modulators of metabotropic glutamate receptors | MERZ PHARMA GMBH & CO., KGAA (DE) | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004001-A1 | Tetrahydroquinolones and their use as modulators of metabotropic glutamate receptors | GRM1, GRM5, GRM2 | PGR 2250/4885GRM5 2/4885CYP3A4 2584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.